- AimedBio and GC cell signs a co-development agreement for a CAR-NK
cell therapy drug.
- The contract aims to derive candidates for
CAR-NK drugs using AimedBio’s 'AMB015' antibodies that bind to cancer-specific proteins.
- Through this collaboration, AimedBio hopes to expand their
antibody-based therapeutics development area from ADCs to cell therapy.